In a matter before the Delaware Chancery Court, CRA was retained by an early-stage pharmaceutical manufacturer whose trade secrets had been misappropriated through its contract manufacturer. The technology at issue described a novel way of developing therapeutic vaccines, was not covered by patents, and was involved in pre-clinical research. To demonstrate harm in the context of many years of risky development and regulatory hurdles, CRA’s expert evaluated the market for private investment in early-stage clinical research and the consequences of losing first-in-class status due to the misappropriation of trade secrets.
IP Literature Watch: June 2025
We are pleased to present the latest edition of CRA’s IP Literature Watch. This issue contains pieces on antitrust & IP, licensing, litigation, innovation, law...